Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,809Revenue (TTM) $M87.0Net Margin (%)303Altman Z-Score7.2
Enterprise Value $M2,901EPS (TTM) $12.2Operating Margin %44.9Piotroski F-Score6
P/E(ttm)11.1Beneish M-Score0.5Pre-tax Margin (%)51.7Higher ROA y-yY
Price/Book7.210-y EBITDA Growth Rate %--Quick Ratio10.7Cash flow > EarningsN
Price/Sales33.65-y EBITDA Growth Rate %--Current Ratio10.9Lower Leverage y-yY
Price/Free Cash Flow89.9y-y EBITDA Growth Rate %109ROA % (ttm)58.8Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)120Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M20.8ROIC % (ttm)118Gross Margin Increase y-yY

Gurus Latest Trades with LGND

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
LGNDJoel Greenblatt 2016-03-31 Buy 0.03%$85.79 - $108.42
($97.41)
$ 136.0740%New holding21,822
LGNDKen Fisher 2015-12-31 Reduce$85.69 - $111.85
($99.19)
$ 136.0737%Reduce -0.14%70,583
LGNDKen Fisher 2015-09-30 Reduce$82.1 - $111.25
($97.26)
$ 136.0740%Reduce -12.31%70,683
LGNDKen Fisher 2015-06-30 Reduce$75.67 - $100.9
($87.3)
$ 136.0756%Reduce -1.59%80,608
LGNDJoel Greenblatt 2015-03-31 Sold Out -0.0016%$51.54 - $77.11
($61.42)
$ 136.07122%Sold Out0
LGNDJoel Greenblatt 2014-12-31 Reduce-0.26%$42.36 - $57.96
($52.25)
$ 136.07160%Reduce -99.32%3,766
LGNDKen Fisher 2014-12-31 Add0.01%$42.36 - $57.96
($52.23)
$ 136.07161%Add 132.31%81,908
LGNDJoel Greenblatt 2014-09-30 Add0.23%$46.99 - $64.52
($53.04)
$ 136.07157%Add 894.83%552,053
LGNDJoel Greenblatt 2014-06-30 Buy 0.04%$59.74 - $70.19
($65.09)
$ 136.07109%New holding55,492
LGNDKen Fisher 2014-06-30 Buy $59.74 - $70.19
($65.09)
$ 136.07109%New holding36,908
LGNDJoel Greenblatt 2014-03-31 Sold Out -0.02%$51.52 - $79.58
($66.37)
$ 136.07105%Sold Out0
LGNDJoel Greenblatt 2013-12-31 Add0.01%$44.86 - $57.95
($52.33)
$ 136.07160%Add 124.95%13,803
LGNDJoel Greenblatt 2013-09-30 Buy 0.01%$38.69 - $49.66
($45.21)
$ 136.07201%New holding6,136
LGNDGeorge Soros 2011-09-30 Sold Out -0.0017%$10.89 - $15.95
($13.18)
$ 136.07932%Sold Out0
LGNDGeorge Soros 2011-06-30 Buy $9.56 - $12.02
($10.55)
$ 136.071190%New holding10,000
LGNDGeorge Soros 2009-12-31 Sold Out $9.96 - $14.16
($12.16)
$ 136.071019%Sold Out0
LGNDGeorge Soros 2009-09-30 Buy $13.74 - $18.9
($16.15)
$ 136.07743%New holding4,483
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

LGND is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


LGND: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
KOZARICH JOHN WDirector 2016-07-01Sell1,000$121.411.12view
KOZARICH JOHN WDirector 2016-06-01Sell1,000$117.4214.89view
Herman Melanie JDirector of Accounting 2016-05-18Sell334$120.511.95view
Aryeh JasonDirector 2016-05-06Sell25,000$119.213.17view
KOZARICH JOHN WDirector 2016-05-02Sell1,000$121.5710.96view
KOZARICH JOHN WDirector 2016-04-06Sell5,000$11517.3view
FOEHR MATTHEW WPresident and COO 2016-03-17Sell6,400$96.739.5view
Aryeh JasonDirector 2016-03-08Sell6,129$101.1833.33view
HIGGINS JOHN LCEO 2016-03-07Sell10,833$102.4731.65view
KOZARICH JOHN WDirector 2016-01-20Sell1,666$94.9442.09view

Quarterly/Annual Reports about LGND:

News about LGND:

Articles On GuruFocus.com
Gurus Invest in Top Biotechnology Stocks Jun 20 2016 
RS Investment Increases Holdings in Ulta Salon, Noble Energy and Fortune Brands Dec 23 2015 
Dan Loeb Sees Opportunity in Latest Activist Target Baxter International Aug 06 2015 
Dan Loeb Sees Opportunity in Latest Activist Target Baxter International Aug 06 2015 
Ligand Pharmaceuticals - Severe competitive threat to key royalty program and “going concern” ri Jun 19 2014 
5 Hot Stocks to Consider Now Mar 30 2012 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) May 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 09 2009 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 04 2009 

More From Other Websites
Ligand Pharmaceuticals (LGND) Jumps: Stock Rises 5.5% Jul 21 2016
Microsoft Sends Dow To 9th Win; eBay, Intel, Mattel Move After Hours Jul 20 2016
Why You Should Be Paying Attention To Facebook, Microsoft's Charts Jul 20 2016
Nasdaq Spikes Higher On Earnings; Breakouts A Dime A Dozen Jul 20 2016
These 5 Top Stocks Are Staging Breakouts Amid Earnings Season Jul 20 2016
Why Does Ligand Pharmaceuticals Have Such an Attractive Margin? Jul 20 2016
How Do Analysts Rate Ligand Pharmaceuticals? Jul 20 2016
Amgen’s Kyprolis with Ligand Pharmaceuticals’s Captisol Technology Jul 20 2016
How Much Potential Does Promacta Hold? Jul 18 2016
Ligand Pharmaceuticals’s Portfolio Pyramid as Its Valuation Catalyst Jul 18 2016
What Is Ligand Pharmaceuticals’s Expected Revenue Growth in 2016? Jul 15 2016
Looking at Ligand Pharmaceuticals’s Revenue Sources Jul 15 2016
Ligand Pharmaceuticals’s Performance Based on EV-to-EBITDA Jul 14 2016
Understanding Ligand Pharmaceuticals’s PE Multiple Jul 14 2016
Ligand to Report Second Quarter Results on August 4th Jul 14 2016
Sage Therapeutics' Post-Partum Depression Drug Scores; Stock Up Jul 12 2016
Ligand (LGND) Signs Deal with Gilead for OmniAb Technology Jul 11 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)